An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension

R. T. Zamanian, D. J. Levine, R. C. Bourge, S. A. De Souza, E. B. Rosenzweig, H. Alnuaimat, Charles Dwayne Burger, S. C. Mathai, N. Leedom, K. DeAngelis, A. Lim, T. De Marco

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to characterize respiratory-related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory-related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)–approved PAH therapies. This was a long-term, prospective, observational study. All respiratory-related AEs were recorded during the study. The number of PAH patients enrolled was 1,333, 666 treated with inhaled treprostinil and 667 controls (treated with an FDA-approved PAH therapy other than inhaled treprostinil), for a total of 958 and 1,094 patient-years of exposure, respectively. In the inhaled-treprostinil group, 1,281 respiratory-related AEs were reported in 403 patients (61%), and in the control group, 1,295 respiratory-related AEs were reported in 388 patients (58%). Cough, throat irritation, nasal discomfort, and hemoptysis were the most common respiratory-related AEs (occurring in ≥2% of patients in either treatment group) that demonstrated a higher number of events per patient-year of exposure in the inhaled-treprostinil group than in the control group (risk ratio [95% confidence interval]: 1.487 [1.172–1.887], 3.777 [2.050–6.956], 2.039 [1.072–3.879], and 1.957 [1.024–3.741], respectively). Overall, inhaled treprostinil was well tolerated by PAH patients in routine clinical care, with respiratory-related AEs consistent with the known safety profile (trial registration: clinicaltrials. gov identifier: NCT01266265).

Original languageEnglish (US)
Pages (from-to)329-337
Number of pages9
JournalPulmonary Circulation
Volume6
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Patient Safety
Pulmonary Hypertension
Observational Studies
United States Food and Drug Administration
Therapeutics
Safety
treprostinil
Control Groups
Hemoptysis
Pharynx
Nose
Cough
Odds Ratio
Prospective Studies
Confidence Intervals
Incidence

Keywords

  • Adverse events
  • Prostacyclin
  • Tolerability

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Zamanian, R. T., Levine, D. J., Bourge, R. C., De Souza, S. A., Rosenzweig, E. B., Alnuaimat, H., ... De Marco, T. (2016). An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. Pulmonary Circulation, 6(3), 329-337. https://doi.org/10.1086/688059

An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. / Zamanian, R. T.; Levine, D. J.; Bourge, R. C.; De Souza, S. A.; Rosenzweig, E. B.; Alnuaimat, H.; Burger, Charles Dwayne; Mathai, S. C.; Leedom, N.; DeAngelis, K.; Lim, A.; De Marco, T.

In: Pulmonary Circulation, Vol. 6, No. 3, 01.09.2016, p. 329-337.

Research output: Contribution to journalArticle

Zamanian, RT, Levine, DJ, Bourge, RC, De Souza, SA, Rosenzweig, EB, Alnuaimat, H, Burger, CD, Mathai, SC, Leedom, N, DeAngelis, K, Lim, A & De Marco, T 2016, 'An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension', Pulmonary Circulation, vol. 6, no. 3, pp. 329-337. https://doi.org/10.1086/688059
Zamanian, R. T. ; Levine, D. J. ; Bourge, R. C. ; De Souza, S. A. ; Rosenzweig, E. B. ; Alnuaimat, H. ; Burger, Charles Dwayne ; Mathai, S. C. ; Leedom, N. ; DeAngelis, K. ; Lim, A. ; De Marco, T. / An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. In: Pulmonary Circulation. 2016 ; Vol. 6, No. 3. pp. 329-337.
@article{c35eaa4d0e99430cb8fbd6d9aa7a943a,
title = "An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension",
abstract = "Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to characterize respiratory-related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory-related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)–approved PAH therapies. This was a long-term, prospective, observational study. All respiratory-related AEs were recorded during the study. The number of PAH patients enrolled was 1,333, 666 treated with inhaled treprostinil and 667 controls (treated with an FDA-approved PAH therapy other than inhaled treprostinil), for a total of 958 and 1,094 patient-years of exposure, respectively. In the inhaled-treprostinil group, 1,281 respiratory-related AEs were reported in 403 patients (61{\%}), and in the control group, 1,295 respiratory-related AEs were reported in 388 patients (58{\%}). Cough, throat irritation, nasal discomfort, and hemoptysis were the most common respiratory-related AEs (occurring in ≥2{\%} of patients in either treatment group) that demonstrated a higher number of events per patient-year of exposure in the inhaled-treprostinil group than in the control group (risk ratio [95{\%} confidence interval]: 1.487 [1.172–1.887], 3.777 [2.050–6.956], 2.039 [1.072–3.879], and 1.957 [1.024–3.741], respectively). Overall, inhaled treprostinil was well tolerated by PAH patients in routine clinical care, with respiratory-related AEs consistent with the known safety profile (trial registration: clinicaltrials. gov identifier: NCT01266265).",
keywords = "Adverse events, Prostacyclin, Tolerability",
author = "Zamanian, {R. T.} and Levine, {D. J.} and Bourge, {R. C.} and {De Souza}, {S. A.} and Rosenzweig, {E. B.} and H. Alnuaimat and Burger, {Charles Dwayne} and Mathai, {S. C.} and N. Leedom and K. DeAngelis and A. Lim and {De Marco}, T.",
year = "2016",
month = "9",
day = "1",
doi = "10.1086/688059",
language = "English (US)",
volume = "6",
pages = "329--337",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "3",

}

TY - JOUR

T1 - An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension

AU - Zamanian, R. T.

AU - Levine, D. J.

AU - Bourge, R. C.

AU - De Souza, S. A.

AU - Rosenzweig, E. B.

AU - Alnuaimat, H.

AU - Burger, Charles Dwayne

AU - Mathai, S. C.

AU - Leedom, N.

AU - DeAngelis, K.

AU - Lim, A.

AU - De Marco, T.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to characterize respiratory-related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory-related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)–approved PAH therapies. This was a long-term, prospective, observational study. All respiratory-related AEs were recorded during the study. The number of PAH patients enrolled was 1,333, 666 treated with inhaled treprostinil and 667 controls (treated with an FDA-approved PAH therapy other than inhaled treprostinil), for a total of 958 and 1,094 patient-years of exposure, respectively. In the inhaled-treprostinil group, 1,281 respiratory-related AEs were reported in 403 patients (61%), and in the control group, 1,295 respiratory-related AEs were reported in 388 patients (58%). Cough, throat irritation, nasal discomfort, and hemoptysis were the most common respiratory-related AEs (occurring in ≥2% of patients in either treatment group) that demonstrated a higher number of events per patient-year of exposure in the inhaled-treprostinil group than in the control group (risk ratio [95% confidence interval]: 1.487 [1.172–1.887], 3.777 [2.050–6.956], 2.039 [1.072–3.879], and 1.957 [1.024–3.741], respectively). Overall, inhaled treprostinil was well tolerated by PAH patients in routine clinical care, with respiratory-related AEs consistent with the known safety profile (trial registration: clinicaltrials. gov identifier: NCT01266265).

AB - Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to characterize respiratory-related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory-related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)–approved PAH therapies. This was a long-term, prospective, observational study. All respiratory-related AEs were recorded during the study. The number of PAH patients enrolled was 1,333, 666 treated with inhaled treprostinil and 667 controls (treated with an FDA-approved PAH therapy other than inhaled treprostinil), for a total of 958 and 1,094 patient-years of exposure, respectively. In the inhaled-treprostinil group, 1,281 respiratory-related AEs were reported in 403 patients (61%), and in the control group, 1,295 respiratory-related AEs were reported in 388 patients (58%). Cough, throat irritation, nasal discomfort, and hemoptysis were the most common respiratory-related AEs (occurring in ≥2% of patients in either treatment group) that demonstrated a higher number of events per patient-year of exposure in the inhaled-treprostinil group than in the control group (risk ratio [95% confidence interval]: 1.487 [1.172–1.887], 3.777 [2.050–6.956], 2.039 [1.072–3.879], and 1.957 [1.024–3.741], respectively). Overall, inhaled treprostinil was well tolerated by PAH patients in routine clinical care, with respiratory-related AEs consistent with the known safety profile (trial registration: clinicaltrials. gov identifier: NCT01266265).

KW - Adverse events

KW - Prostacyclin

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84987654739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987654739&partnerID=8YFLogxK

U2 - 10.1086/688059

DO - 10.1086/688059

M3 - Article

AN - SCOPUS:84987654739

VL - 6

SP - 329

EP - 337

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 3

ER -